0001214659-19-001618.txt : 20190227 0001214659-19-001618.hdr.sgml : 20190227 20190227190011 ACCESSION NUMBER: 0001214659-19-001618 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190225 FILED AS OF DATE: 20190227 DATE AS OF CHANGE: 20190227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BAUM CHARLES M CENTRAL INDEX KEY: 0001579824 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35921 FILM NUMBER: 19639704 MAIL ADDRESS: STREET 1: C/O MIRATI THERAPEUTICS INC. STREET 2: 9393 TOWNE CENTRE DRIVE, STE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mirati Therapeutics, Inc. CENTRAL INDEX KEY: 0001576263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462693615 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-332-3410 MAIL ADDRESS: STREET 1: 9393 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 marketforms-44229.xml PRIMARY DOCUMENT X0306 4 2019-02-25 0001576263 Mirati Therapeutics, Inc. MRTX 0001579824 BAUM CHARLES M C/O MIRATI THERAPEUTICS INC. 9393 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121 true true false false President & CEO Common Stock 2019-02-25 4 M false 51810 8.50 A 117851 D Common Stock 2019-02-25 4 S false 25722 75.1712 D 92129 D Common Stock 2019-02-25 4 S false 18235 75.7687 D 73894 D Common Stock 2019-02-25 4 S false 5687 76.7545 D 68207 D Common Stock 2019-02-25 4 S false 2066 77.9593 D 66141 D Common Stock 2019-02-25 4 S false 100 79.09 D 66041 D Common Stock 8.5 2019-02-25 4 M false 51810 0 D 2020-07-16 Common Stock 51810 51810 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2017. This transaction was executed in multiple trades at prices ranging from $74.43 to $75.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $75.430 to $76.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $76.435 to $77.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $77.545 to $78.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. 20% of the shares subject to the stock option vested and became exercisable on the Date of Grant and 20% of the shares vested on each of the 1st 2nd, 3rd and 4th anniversaries of November 12, 2012. The options expire on July 16, 2020. /s/ Vickie Reed, Attorney-in-Fact 2019-02-27